GU Cancers 2020 | SIP-T: autologous T-cells for prostate cancer

VJOncology is committed to improving our service to you

Daniel Petrylak

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the association between humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T (SIP-T) treatment in two Phase II clinical studies: STAMP and STRIDE. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter